Transfusion-related red blood cell alloantibodies: Induction and consequences

Blood

Volumn 133, Issue 17, 2019, Pages 1821-1830

  Tormey, Christopher A ^a,b   Hendrickson, Jeanne E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIGEN;

ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION REACTION; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEMOLYTIC ANEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADVERSE EVENT; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; IMMUNOLOGY;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; ISOANTIBODIES; TRANSFUSION REACTION;

EID: 85065302256     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-08-833962     Document Type: Review

References (115)

1. US Department of Health and Human Services (FDA). Fatalities Reported to the FDA Following Blood Collection. http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability. Accessed 1 August 2018.
2. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(Suppl 2):1588-1598.
3. Yazer MH, Jackson B, Beckman N, et al; Biomedical Excellence for Safer Transfusions (BEST) Collaborative. Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study. Transfusion. 2016; 56(8):1965-1973.
4. Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004;41(2):93-117.
5. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion. 2008;48(10): 2069-2076.
6. Gibb DR, Liu J, Natarajan P, et al. Type I IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice. J Immunol. 2017;199(3):1041-1050.
7. Arthur CM, Patel SR, Smith NH, et al. Antigen density dictates immune responsiveness following red blood cell transfusion. J Immunol. 2017;198(7):2671-2680.
8. Kwon DH, Sandler SG, Flegel WA. DEL phenotype. Immunohematology. 2017; 33(3):125-132.
9. Chou ST, Evans P, Vege S, et al. RH genotype matching for transfusion support in sickle cell disease. Blood. 2018;132(11):1198-1207.
10. Hendrickson JE, Tormey CA. Rhesus pieces: genotype matching of RBCs. Blood. 2018; 132(11):1091-1093.
11. Chou ST, Flanagan JM, Vege S, et al. Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Adv. 2017;1(18): 1414-1422.
12. Picard C, Frassati C, Basire A, et al. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Transfusion. 2009; 49(11):2412-2417.
13. Chiaroni J, Dettori I, Ferrera V, et al. HLA-DRB1 polymorphism is associated with Kell immunisation. Br J Haematol. 2006;132(3): 374-378.
14. Reviron D, Dettori I, Ferrera V, et al. HLA-DRB1 alleles and Jk(a) immunization. Transfusion. 2005;45(6):956-959.
15. Tatari-Calderone Z, Gordish-Dressman H, Fasano R, et al. Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease. Hum Immunol. 2016;77(1):35-40.
16. Schonewille H, Doxiadis II, Levering WH, Roelen DL, Claas FH, Brand A. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion. 2014;54(8): 1971-1980.
17. Baleotti W Jr, Ruiz MO, Fabron A Jr, Castilho L, Giuliatti S, Donadi EA. HLA-DRB1*07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population. Transfusion. 2014;54(10):2468-2476.
18. Chu CC, Ho HT, Lee HL, et al. Anti-“Mi(a)” immunization is associated with HLA-DRB1*0901. Transfusion. 2009;49(3): 472-478.
19. Verduin EP, Brand A, van de Watering LM, et al. The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness. Transfusion. 2016;56(7):1849-1856.
20. Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol. 2015;171(5):671-682.
21. Hendrickson JE, Tormey CA. Red blood cell antibodies in hematology/oncology patients: interpretation of immunohemato-logic tests and clinical significance of detected antibodies. Hematol Oncol Clin North Am. 2016;30(3):635-651.
22. Liu C, Grossman BJ. Antibody of undetermined specificity: frequency, laboratory features, and natural history. Transfusion. 2013;53(5):931-938.
23. Howie HL, Wang X, Kapp L, Lebedev JN, Zimring JC. Identification of IgG3-specific epitope that remedies problem in diagnostic IgG subclass determination due to human genetic variation. J Clin Pathol. 2018;71(6): 559-561.
24. Hadley AG, Wilkes A, Goodrick J, Penman D, Soothill P, Lucas G. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br J Obstet Gynaecol. 1998;105(2):231-234.
25. Nance SJ, Nelson JM, Horenstein J, Arndt PA, Platt LD, Garratty G. Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol. 1989;92(1):89-92.
26. Kapur R, Della Valle L, Sonneveld M, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol. 2014;166(6):936-945. cell disease. Am J Hematol. 2016;91(12): 1181-1184.
27. Sonneveld ME, Plom R, Admiraal J, et al. IgG alloantibodies against RBC induced by pregnancy or transfusion have unique glycosylation patterns which correlate with clinical outcomes of hemolytic disease of the fetus or newborn [abstract]. Blood. 2015; 126(23). Abstract 660.
28. Unni N, Peddinghaus M, Tormey CA, Stack G. Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion. 2014;54(1):98-103.
29. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49(3):505-512.
30. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015;90(12):1135-1141.
31. Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion. 2016;56(11):2662-2667.
32. Siddon AJ, Kenney BC, Hendrickson JE, Tormey CA. Delayed haemolytic and serologic transfusion reactions: pathophysiology, treatment and prevention. Curr Opin Hematol. 2018;25(6):459-467.
33. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood. 2009; 114(19):4279-4282.
34. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: first-year experience. Transfusion. 2010; 50(7):1465-1470.
35. Sloan SR. The importance of antibody screens after transfusions. Transfusion. 2016; 56(11):2653-2654.
36. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170(6):745-756.
37. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12): 1181-1184.
38. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
39. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2016;56(1):107-114.
40. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9): 1785-1792.
41. Mwesigwa S, Moulds JM, Chen A, et al. Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion. 2018;58(3): 726-735.
42. Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment. Transfus Clin Biol. 2017;24(3):227-231.
43. Chonat S, Quarmyne MO, Bennett CM, et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018;103(10):e483-e485.
44. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev. 2016;30(4):159-164.
45. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120(5):1132-1139.
46. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015: 146-151.
47. Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematology. 2006;22(4):188-195.
48. Schonewille H, Prinsen-Zander KJ, Reijnart M, et al. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation. Transfusion. 2015; 55(12):2912-2919, quiz 2911.
49. Stussi G, Halter J, Bucheli E, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009;94(2): 239-248.
50. Webb J, Abraham A. Complex transfusion issues in pediatric hematopoietic stem cell transplantation. Transfus Med Rev. 2016; 30(4):202-208.
51. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling al-logeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48-56.
52. Hamilton MS, Singh V, Warady BA. Plasma cell-rich acute cellular rejection of a transplanted kidney associated with antibody to the red cell Kidd antigen. Pediatr Transplant. 2006;10(8):974-977.
53. Lerut E, Van Damme B, Noizat-Pirenne F, et al. Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion. 2007; 47(1):28-40.
54. Rourk A, Squires JE. Implications of the Kidd blood group system in renal transplantation. Immunohematology. 2012;28(3):90-94.
55. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013; 122(6):1062-1071.
56. Hendrickson JE, Eisenbarth SC, Tormey CA. Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Curr Opin Hematol. 2016; 23(6):543-549.
57. Fasano RM, Booth GS, Miles MR, et al. Red blood cell alloimmunization is influenced by inflammatory status at the time of transfusion in patients with sickle cell disease [abstract]. Blood. 2013;122(21). Abstract 40.
58. Evers D, van der Bom JG, Tijmensen J, et al. Red cell alloimmunisation in patients with different types of infections. Br J Haematol. 2016;175(5):956-966.
59. Celli R, Schulz W, Hendrickson JE, Tormey CA. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sang. 2017;112(5):469-472.
60. Ryder AB, Hendrickson JE, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematol. 2016;174(3): 483-485.
61. Singhal D, Kutyna MM, Chhetri R, et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica. 2017; 102(12):2021-2029.
62. Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion. 2014;54(4):972-981, quiz 971.
63. Karafin MS, Westlake M, Hauser RG, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol. 2018;181(5):672-681.
64. Azarkeivan A, Ansari S, Ahmadi MH, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol. 2011;28(6):479-485.
65. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia [see comment]. Vox Sang. 1990;58(1):50-55.
66. Papay P, Hackner K, Vogelsang H, et al. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med. 2012;125(7):717.e711-718.
67. Arora K, Kelley J, Sui D, et al. Cancer type predicts alloimmunization following RhD-incompatible RBC transfusions. Transfusion. 2017;57(4):952-958.
68. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion. 2014;54(8):1981-1987.
69. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders [see comment]. Blood. 2008; 112(6):2546-2553.
70. Tatari-Calderone Z, Minniti CP, Kratovil T, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol. 2009;47(1):64-70.
71. Tatari-Calderone Z, Tamouza R, Le Bouder GP, et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol. 2013;2013: 937846.
72. Hanchard NA, Moulds JM, Belmont JW, Chen A. A genome-wide screen for large-effect alloimmunization susceptibility loci among red blood cell transfusion recipients with sickle cell disease. Transfus Med Hemother. 2014;41(6):453-461.
73. Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood. 2012; 119(6):1566-1569.
74. Karafin MS, Tan S, Tormey CA, et al. Prevalence and risk factors for RBC alloantibodies in blooddonors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion. 2019;59(1): 217-225.
75. Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion. 2003;43(7): 945-952.
76. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent [see comment]. Blood. 2000;96(10):3369-3373.
77. Ryder AB, Zimring JC, Hendrickson JE. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother. 2014;41(6): 406-419.
78. Land WG. Transfusion-related acute lung injury: the work of DAMPs. Transfus Med Hemother. 2013;40(1):3-13.
79. Radwanski K, Garraud O, Cognasse F, Hamzeh-Cognasse H, Payrat JM, Min K. The effects of red blood cell preparation method on in vitro markers of red blood cell aging and inflammatory response. Transfusion. 2013;53(12):3128-3138.
80. Thibault L, Beauséjour A, de Grandmont MJ, Lemieux R, Leblanc JF. Characterization of blood components prepared from whole-blood donations after a 24-hour hold with the platelet-rich plasma method. Transfusion. 2006;46(8):1292-1299.
81. Tormey CA, Hendrickson JE. Irradiation of red blood cells and alloimmunization. Lab Med. 2017;48(2):172-177.
82. Rapido F, Brittenham GM, Bandyopadhyay S, et al. Prolonged red cell storage before transfusion increases extravascular hemolysis. J Clin Invest. 2017;127(1):375-382.
83. Yazer MH, Triulzi DJ. Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization. Am J Clin Pathol. 2010;134(3):443-447.
84. Zalpuri S, Schonewille H, Middelburg R, et al. Effect of storage of red blood cells on alloimmunization. Transfusion. 2013;53(11): 2795-2800.
85. Dinardo CL, Fernandes FL, Sampaio LR, Sabino EC, Mendrone A Jr. Transfusion of older red blood cell units, cytokine burst and alloimmunization: a case-control study. Rev Bras Hematol Hemoter. 2015;37(5):320-323.
86. Desai PC, Deal AM, Pfaff ER, et al. Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease. Am J Hematol. 2015;90(8):691-695.
87. Kanias T, Sinchar D, Osei-Hwedieh D, et al. Testosterone-dependent sex differences in red blood cell hemolysis in storage, stress, and disease. Transfusion. 2016;56(10): 2571-2583.
88. Kanias T, Lanteri MC, Page GP, et al. Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. Blood Adv. 2017;1(15):1132-1141.
89. Francis RO, Jhang J, Hendrickson JE, Zimring JC, Hod EA, Spitalnik SL. Frequency of glucose-6-phosphate dehydrogenase-deficient red blood cell units in a metropolitan transfusion service. Transfusion. 2013; 53(3):606-611.
90. Osei-Hwedieh DO, Kanias T, Croix CS, et al. Sickle cell trait increases red blood cell storage hemolysis and post-transfusion clearance in mice. EBioMedicine. 2016;11: 239-248.
91. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report. http://www.nhlbi.nih.gov/health-pro-guidelines/sickle-cell-disease-guidelines. Accessed 1 August 2018.
92. Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion. 2015;55(6 Pt 2):1388-1393.
93. Lin Y, Saskin A, Wells RA, et al. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. Vox Sang. 2017;112(1):79-86.
94. Shirey RS, Boyd JS, Parwani AV, Tanz WS, Ness PM, King KE. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion. 2002;42(11): 1435-1441.
95. Gibb DR, Liu J, Santhanakrishnan M, et al. B cells require Type 1 interferon to produce alloantibodies to transfused KEL-expressing red blood cells in mice. Transfusion. 2017; 57(11):2595-2608.
96. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-2781.
97. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood. 2009;114(11):2315-2322.
98. Smith NH, Henry KL, Cadwell CM, et al. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion. 2012;52(12):2620-2630.
99. Auffray I, Marfatia S, de Jong K, et al. Glycophorin A dimerization and band 3 interaction during erythroid membrane biogenesis: in vivo studies in human glycophorin A transgenic mice. Blood. 2001;97(9): 2872-2878.
100. Hendrickson JE, Desmarets M, Deshpande SS, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion. 2006;46(9):1526-1536.
101. Natarajan P, Liu D, Patel SR, et al. CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model. Front Immunol. 2017;8:907.
102. Patel SR, Bennett A, Girard-Pierce K, et al. Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice. Blood Adv. 2018;2(2): 105-115.
103. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol. 2007;82(8):691-696.
104. Bao W, Yu J, Heck S, Yazdanbakhsh K. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood. 2009;113(22):5624-5627.
105. Arneja A, Salazar JE, Jiang W, Hendrickson JE, Zimring JC, Luckey CJ. Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica. 2016;101(11):e440-e444.
106. Calabro S, Gallman A, Gowthaman U, et al. Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med. 2016;213(6):887-896.
107. Mener A, Arthur CM, Patel SR, Liu J, Hendrickson JE, Stowell SR. Complement component 3 negatively regulates antibody response by modulation of red blood cell antigen. Front Immunol. 2018;9:676.
108. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood. 2007;110(6):2201-2208.
109. Cadwell CM, Zimring JC. Cross-linking induces non-haemolytic antigen-loss from transfused red blood cells: a potential role for rheumatoid factor. Vox Sang. 2008;95(2): 159-162.
110. Stowell SR, Liepkalns JS, Hendrickson JE, et al. Antigen modulation confers protection to red blood cells from antibody through Fcg receptor ligation. J Immunol. 2013;191(10): 5013-5025.
111. Stowell SR, Arthur CM, Girard-Pierce KR, et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica. 2015;100(10): e394-e397.
112. Liu J, Santhanakrishnan M, Natarajan P, et al. Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood. 2016;128(26):3159-3168.
113. Hod EA, Cadwell CM, Liepkalns JS, et al. Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions. Blood. 2008;112(3):891-894.
114. Hod EA, Arinsburg SA, Francis RO, Hendrickson JE, Zimring JC, Spitalnik SL. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sang. 2010;99(2):99-111.
115. Liepkalns JS, Hod EA, Stowell SR, Cadwell CM, Spitalnik SL, Zimring JC. Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcg receptors in a murine model. Transfusion. 2012;52(12): 2631-2645.